Back to Search Start Over

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Authors :
Karsa, M
Xiao, L
Ronca, E
Bongers, A
Spurling, D
Karsa, A
Cantilena, S
Mariana, A
Failes, TW ; https://orcid.org/0000-0003-4618-1057
Arndt, GM
Cheung, LC
Kotecha, RS
Sutton, R ; https://orcid.org/0000-0002-0188-6005
Lock, RB ; https://orcid.org/0000-0002-3436-9071
Williams, O
de Boer, J
Haber, M ; https://orcid.org/0000-0003-2036-8817
Norris, MD ; https://orcid.org/0000-0002-0632-4589
Henderson, MJ ; https://orcid.org/0000-0003-2741-3852
Somers, K ; https://orcid.org/0000-0002-7644-4121
Karsa, M
Xiao, L
Ronca, E
Bongers, A
Spurling, D
Karsa, A
Cantilena, S
Mariana, A
Failes, TW ; https://orcid.org/0000-0003-4618-1057
Arndt, GM
Cheung, LC
Kotecha, RS
Sutton, R ; https://orcid.org/0000-0002-0188-6005
Lock, RB ; https://orcid.org/0000-0002-3436-9071
Williams, O
de Boer, J
Haber, M ; https://orcid.org/0000-0003-2036-8817
Norris, MD ; https://orcid.org/0000-0002-0632-4589
Henderson, MJ ; https://orcid.org/0000-0003-2741-3852
Somers, K ; https://orcid.org/0000-0002-7644-4121
Source :
urn:ISSN:0946-2716; urn:ISSN:1432-1440; Journal of Molecular Medicine, 102, 4, 507-519
Publication Year :
2024

Abstract

Acute leukemia continues to be a major cause of death from disease worldwide and current chemotherapeutic agents are associated with significant morbidity in survivors. While better and safer treatments for acute leukemia are urgently needed, standard drug development pipelines are lengthy and drug repurposing therefore provides a promising approach. Our previous evaluation of FDA-approved drugs for their antileukemic activity identified disulfiram, used for the treatment of alcoholism, as a candidate hit compound. This study assessed the biological effects of disulfiram on leukemia cells and evaluated its potential as a treatment strategy. We found that disulfiram inhibits the viability of a diverse panel of acute lymphoblastic and myeloid leukemia cell lines (n = 16) and patient-derived xenograft cells from patients with poor outcome and treatment-resistant disease (n = 15). The drug induced oxidative stress and apoptosis in leukemia cells within hours of treatment and was able to potentiate the effects of daunorubicin, etoposide, topotecan, cytarabine, and mitoxantrone chemotherapy. Upon combining disulfiram with auranofin, a drug approved for the treatment of rheumatoid arthritis that was previously shown to exert antileukemic effects, strong and consistent synergy was observed across a diverse panel of acute leukemia cell lines, the mechanism of which was based on enhanced ROS induction. Acute leukemia cells were more sensitive to the cytotoxic activity of disulfiram than solid cancer cell lines and non-malignant cells. While disulfiram is currently under investigation in clinical trials for solid cancers, this study provides evidence for the potential of disulfiram for acute leukemia treatment. Key messages: Disulfiram induces rapid apoptosis in leukemia cells by boosting oxidative stress. Disulfiram inhibits leukemia cell growth more potently than solid cancer cell growth. Disulfiram can enhance the antileukemic efficacy of chemotherapies. Disulfira

Details

Database :
OAIster
Journal :
urn:ISSN:0946-2716; urn:ISSN:1432-1440; Journal of Molecular Medicine, 102, 4, 507-519
Publication Type :
Electronic Resource
Accession number :
edsoai.on1458862657
Document Type :
Electronic Resource